Focus Investment Banking

JULY 31, 2023

This article focuses on how medical practices are valued by private equity-backed groups, and to an extent, health systems and other strategic acquirers. EBITDA is typically calculated using the steps below: Determine the practice’s net profit in the most recent twelve-month period. COVID-19 related payments) or absences (e.g.,

Medical 52

Medical Private Equity Healthcare Professional Services 52

Tyton Partners

APRIL 10, 2024

Achieve Partners’ social impact focus and deep experience in the digital transformation of education makes them the perfect partner for Elentra to continue to scale its purpose-built platform, and acquire other solutions, to best serve medical and allied health institutions globally.

Education 52

Education Medical Private Equity Equities 52

Periculum Capital

MAY 14, 2024

Periculum Capital Company, LLC is pleased to announce it has advised Micro-Dyn Medical Systems, Inc., The firm’s primary services include M&A, capital markets, and restructuring advisory, as well as specialized merchant banking services. a leading health care software company, in its acquisition by The Brydon Group.

Sale 52

Sale IT Mergers and Acquisitions Actuary 52

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 22, 2020

A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2 Year of the Life Sciences Mega-Deals. billion acquisition of The Medicines Company.

M&A 40

M&A Pharmaceutical Acquisitions Capital 40

Cooley M&A

JANUARY 20, 2022

19 treatments from Pfizer, Merck and potentially others hitting the market soon , we expect Big Pharma to continue to parlay this cash flow into growth in other areas of strategic focus. The strong capital markets environment that has prevailed during the past few years has enabled a large number of development-stage and one?product,

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40